All articles by GlobalData Healthcare

Biotech recovery in Q3 2025 as venture funding grows 70.9% from Q2 2025

GlobalData’s Venture Capital Investment Trends In Pharma – Q3 2025 report revealed that the biotech industry witnessed a 70.9% increase…
ESMO 2025: Hengrui’s immunotherapy combo shows perioperative benefit in HCC

On Saturday 19 October 2025, at the European Society for Medical Oncology (ESMO), held in Berlin, Germany, Hengrui presented results…
AAO 2025: EYP-1901 continues to show promise in DME and wAMD

At the 129th Annual Meeting of the American Academy of Ophthalmology (AAO) 2025 in Orlando, Florida, EyePoint Pharmaceuticals presented updates…
ESMO 2025: Novartis’s Pluvicto delays progression to end-stage for mHSPC

At the European Society of Medical Oncology (ESMO) Congress 2025, held in Berlin, Germany from 17 to 21 October, results…
ESMO25: Keytruda combo defies doubt, delivers PFS and OS gains in ovarian cancer

Platinum-resistant ovarian cancer (PROC) remains one of the most treatment-refractory malignancies, with a median overall survival (OS) of less than…

ESMO 2025: Padcev/Keytruda combo has potential as new SOC for perioperative bladder cancer

Results from the Phase III registrational EV-303/KEYNOTE-905 study evaluating the combination of Pfizer’s and Astellas’ nectin-4 targeting antibody-drug conjugate Padcev…
Venture financing for mRNA-based vaccines declines 82% in 2025 YTD

Venture financing for messenger ribonucleic acid (mRNA)-based innovator vaccines declined by 82% from $510m in 2023 to $90m in the 2025's…
ERS 2025: Long-term CFTR use shows clinical benefit but variable microbial impact

At the 2025 European Respiratory Society (ERS) International Congress taking place in Amsterdam, the Netherlands, from 27 September to 1…
ERS 2025: APG808 to address need for biologic for moderate asthma

At the 2025 European Respiratory Society (ERS) International Congress takig place in Amsterdam, the Netherlands, from 27 September to 1…
Expanding GLP-1 horizons: Novo Nordisk leads MASH therapeutic race

On 15 August 2025, Novo Nordisk’s Wegovy (semaglutide 2.4mg) received accelerated approval from the US Food and Drug Administration for…